Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)

NCT01241734 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT01241734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01241734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Lenalidomide in Combination With Rituximab, Ifosfamide, Etoposide, and Carboplatin (RICER)
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2010
Completion date
September 22, 2015
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma